Stock P2OD34 INSULET CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Insulet Corporation Sao Paulo

Equities

P2OD34

BRP2ODBDR009

Market Closed - Sao Paulo
Other stock markets
 17:54:31 24/06/2024 BST 		5-day change 1st Jan Change
36.66 BRL +14.35% Intraday chart for Insulet Corporation -.--% -24.41%
06-24 Transcript : Insulet Corporation - Special Call
06-22 Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
No Evidence, No Injunction; Federal Circuit Vacated Preliminary Injunction For Lack Of Evidence
AQ
US District Court In Puerto Rico Rejects Distributor's Efforts To Hold Wholesalers Liable For A Terminated Agreement Under Puerto Rico Law 75
AQ
The Defend Trade Secrets Act: Key Takeaways From The Federal Circuit's Insulet V. EOFlow Decision
AQ
Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
BU
Insulet : Market Opportunity & Impact of GLP-1’s Update
PU
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
BU
Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
BU
Insulet : 2023 Conflict Minerals Policy
PU
Insulet to Present at the Jefferies Global Healthcare Conference
BU
Preliminarily Enjoin Alleged Trade Secret Misappropriation Without Addressing A Time Bar Defense Under The DTSA?
AQ
Insulet: Q1 Earnings Snapshot
AQ
Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
BU
Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
BU
Insulet : 2023 ESG Data
PU
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
BU
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
BU
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
BU
Insulet to Present Results from First Omnipod 5 Randomized Controlled Trial at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
AQ
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
BU
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PODD Stock
  4. P2OD34 Stock
  5. News Insulet Corporation
  6. Press Releases